Breaking News, Collaborations & Alliances

Minaris and bluebird bio Enter Manufacturing Pact

The CDMO will be the commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona (elivaldogene autotemcel, Lenti-D), a product of bluebird bio, Inc. The European Commission (EC) has granted marketing authorization for Skysona, the first and only gene therapy for patients with Early Cerebral Adrenoleukodystrophy (CALD), a life-threatening progressive neurodegenerative disease....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters